Alzheimer's Disease And Dementia

FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions

FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions

By

Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.

Treating Apathy in Alzheimer Disease Patients: A Meta-Analysis

Treating Apathy in Alzheimer Disease Patients: A Meta-Analysis

By

Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.

Certain Anticholinergic Drugs Appear to Raise Dementia Risk

Certain Anticholinergic Drugs Appear to Raise Dementia Risk

Use of anticholinergic drugs may be tied to a future diagnosis of dementia.

Melanoma, Nonmelanoma Skin Cancer Associated With Reduced Risk for Alzheimer's

Melanoma, Nonmelanoma Skin Cancer Associated With Reduced Risk for Alzheimer's

By

Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

By

Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.

Concern for Employer, Insurance Discrimination for Alzheimer's Patients

Concern for Employer, Insurance Discrimination for Alzheimer's Patients

About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.

Nurse Education Improves Post-Op Survival in Dementia Patients

Nurse Education Improves Post-Op Survival in Dementia Patients

Findings show lower post-surgical mortality among patients with Alzheimer's disease.

Preclinical Alzheimer's Identified With Molecular Markers

Preclinical Alzheimer's Identified With Molecular Markers

Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.

Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued

Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued

By

Merck announced the discontinuation of the Phase 3 APECS study for the treatment of AD.

Positive Opinions on Age May Help Ward Off Dementia

Positive Opinions on Age May Help Ward Off Dementia

Positive beliefs on age may protect against dementia.

Alzheimer Disease May Benefit From Deep Brain Stimulation

Alzheimer Disease May Benefit From Deep Brain Stimulation

The use of DBS in patients with Alzheimer disease is well tolerated and associated with less decline on the CDR-SB.

Healthy Lifestyle May Protect Against Dementia in Older Adult Carriers of APOE ε4

Healthy Lifestyle May Protect Against Dementia in Older Adult Carriers of APOE ε4

By

A study was conducted to assess potential beneficial effects of a lifestyle intervention program on cognition in carriers of the APOE ε4 allele.

Solanezumab Has No Effect on Cognitive Decline in Alzheimer Disease

Solanezumab Has No Effect on Cognitive Decline in Alzheimer Disease

Solanezumab does not alter cognitive decline in patients with mild Alzheimer disease.

Alternative Genetic Risk Variant for Alzheimer Disease Identified

Alternative Genetic Risk Variant for Alzheimer Disease Identified

Brain amyloidosis is associated with certain Alzheimer disease risk variants.

Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are

Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are

By

Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.

No Cognitive Improvement With Idalopirdine in Mild Alzheimer Disease

No Cognitive Improvement With Idalopirdine in Mild Alzheimer Disease

For patients with mild-to-moderate Alzheimer disease, the use of idalopirdine does not improve cognition.

Increased Dementia Risk Seen in Rheumatic Diseases

Increased Dementia Risk Seen in Rheumatic Diseases

There is an increased risk of dementia for patients with rheumatic diseases.

Limited Evidence Supports Physical Interventions for Dementia Prevention

Limited Evidence Supports Physical Interventions for Dementia Prevention

A hanful of studies reviewed the different types of interventions to prevent late-life dementia.

Obesity and Alzheimer Disease: Exploring Risk Modification

Obesity and Alzheimer Disease: Exploring Risk Modification

By

Throughout the life course, higher body mass index and obesity are linked to cognitive decline, brain atrophy, reduced white matter and integrity of the blood-brain barrier, and elevated risk for late-onset Alzheimer disease.

Number of Americans With Alzheimer Disease Expected to More Than Double by 2060

Number of Americans With Alzheimer Disease Expected to More Than Double by 2060

It is predicted that by 2060, a total of 15 million American's will have clinical Alzheimer disease or mild cognitive impairment.

Memory Scores May Not Be Good Alzheimer's Screening Tool

Memory Scores May Not Be Good Alzheimer's Screening Tool

Low memory scores are an early marker for amyloid positivity, but not for measuring early Alzheimer's disease.

Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model

Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model

For improving cognition in a mouse model of AD, combining environmental enrichment and MgT is more effective than either alone.

MRI, CSF Biomarkers Predictive of Alzheimer's Dementia Risk

MRI, CSF Biomarkers Predictive of Alzheimer's Dementia Risk

By

The findings may be particularly useful at the individual level to determine personalized risk of progression to Alzheimer's dementia.

Predicting Alzheimer Dementia Risk With CSF, MRI Clinical Biomarkers

Predicting Alzheimer Dementia Risk With CSF, MRI Clinical Biomarkers

By

There is an urgent need for individualized risk assessments for patients with mild cognitive impairment.

Novel Alzheimer Drug Wins FDA Fast-Track Designation

Novel Alzheimer Drug Wins FDA Fast-Track Designation

By

The FDA has granted Fast Track status to an investigational agent for the treatment of Alzheimer disease.

Intepirdine Shows No Significant Benefit  for Alzheimer Disease

Intepirdine Shows No Significant Benefit for Alzheimer Disease

By

Axovant Sciences announced that intepirdine did not meet its primary endpoints.

Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype

Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype

By

The APOE ε2/ε3 genotype was associated with a protective effect in women and decreased their AD risk to a greater degree than men.

Some Women Face Extended High-Risk Period of Developing Alzheimer's

Some Women Face Extended High-Risk Period of Developing Alzheimer's

Some female carriers of the APOE4 gene have a 10-year window where they are more likely to develop Alzheimer's than men.

Majority of Dementia Care Costs Fall on Families

Majority of Dementia Care Costs Fall on Families

Lifetime care costs are increased for people with dementia.

Early Markers of Alzheimer's Disease Identified

Early Markers of Alzheimer's Disease Identified

By

Depressive symptoms could be used as an early detection marker of Alzheimer's disease.

Sign Up for Free e-newsletters

CME Focus